Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family.

Hasegawa H, Mizoguchi I, Chiba Y, Ohashi M, Xu M, Yoshimoto T.

Front Immunol. 2016 Nov 4;7:479. eCollection 2016. Review.

2.

Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine.

Moudra A, Hubackova S, Machalova V, Vancurova M, Bartek J, Reinis M, Hodny Z, Jonasova A.

Oncoimmunology. 2016 May 13;5(10):e1183860. eCollection 2016.

PMID:
27853634
3.

IL27 controls skin tumorigenesis via accumulation of ETAR-positive CD11b cells in the pre-malignant skin.

Dibra D, Mitra A, Newman M, Xia X, Keenan C, Cutrera JJ, Mathis JM, Wang XJ, Myers J, Li S.

Oncotarget. 2016 Nov 22;7(47):77138-77151. doi: 10.18632/oncotarget.12581.

4.

IL-27 Promotes Proliferation of Human Leukemic Cell Lines Through the MAPK/ERK Signaling Pathway and Suppresses Sensitivity to Chemotherapeutic Drugs.

Jia H, Dilger P, Bird C, Wadhwa M.

J Interferon Cytokine Res. 2016 May;36(5):302-16. doi: 10.1089/jir.2015.0091. Epub 2016 Jan 27.

5.

Promotion of Expansion and Differentiation of Hematopoietic Stem Cells by Interleukin-27 into Myeloid Progenitors to Control Infection in Emergency Myelopoiesis.

Furusawa J, Mizoguchi I, Chiba Y, Hisada M, Kobayashi F, Yoshida H, Nakae S, Tsuchida A, Matsumoto T, Ema H, Mizuguchi J, Yoshimoto T.

PLoS Pathog. 2016 Mar 18;12(3):e1005507. doi: 10.1371/journal.ppat.1005507. eCollection 2016 Mar.

6.

Potential clinical application of interleukin-27 as an antitumor agent.

Yoshimoto T, Chiba Y, Furusawa J, Xu M, Tsunoda R, Higuchi K, Mizoguchi I.

Cancer Sci. 2015 Sep;106(9):1103-10. doi: 10.1111/cas.12731. Epub 2015 Aug 6. Review.

7.

Postpartal subclinical endometritis alters transcriptome profiles in liver and adipose tissue of dairy cows.

Akbar H, Cardoso FC, Meier S, Burke C, McDougall S, Mitchell M, Walker C, Rodriguez-Zas SL, Everts RE, Lewin HA, Roche JR, Loor JJ.

Bioinform Biol Insights. 2014 Feb 19;8:45-63. doi: 10.4137/BBI.S13735. eCollection 2014.

8.

Performance status in elderly patients with acute myeloid leukemia: exploring gene expression signatures of cytokines and chemokines.

Nipp RD, Rao AV.

J Gerontol A Biol Sci Med Sci. 2015 Jun;70(6):714-21. doi: 10.1093/gerona/glt039. Epub 2013 Jun 19.

9.

Interleukin-27: balancing protective and pathological immunity.

Hunter CA, Kastelein R.

Immunity. 2012 Dec 14;37(6):960-9. doi: 10.1016/j.immuni.2012.11.003. Review.

10.

The emerging role of Interleukin 27 in inflammatory arthritis and bone destruction.

Adamopoulos IE, Pflanz S.

Cytokine Growth Factor Rev. 2013 Apr;24(2):115-21. doi: 10.1016/j.cytogfr.2012.10.001. Epub 2012 Nov 16. Review.

11.

Role of STAT3 in Transformation and Drug Resistance in CML.

Nair RR, Tolentino JH, Hazlehurst LA.

Front Oncol. 2012 Apr 10;2:30. doi: 10.3389/fonc.2012.00030. eCollection 2012.

12.

Effects of STAT3 gene silencing and rapamycin on apoptosis in hepatocarcinoma cells.

Zhang Y, Zhang JW, Lv GY, Xie SL, Wang GY.

Int J Med Sci. 2012;9(3):216-24. doi: 10.7150/ijms.4004. Epub 2012 Mar 7.

13.

The current concept of T (h) 17 cells and their expanding role in systemic lupus erythematosus.

Perry D, Peck AB, Carcamo WC, Morel L, Nguyen CQ.

Arthritis. 2011;2011:810649. doi: 10.1155/2011/810649. Epub 2011 Mar 22.

14.

Signaling events involved in interleukin 27 (IL-27)-induced proliferation of human naive CD4+ T cells and B cells.

Charlot-Rabiega P, Bardel E, Dietrich C, Kastelein R, Devergne O.

J Biol Chem. 2011 Aug 5;286(31):27350-62. doi: 10.1074/jbc.M111.221010. Epub 2011 Jun 13.

15.

Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity.

Lambert QT, Pradhan A, Roll JD, Reuther GW.

Biochem J. 2011 Aug 15;438(1):155-64. doi: 10.1042/BJ20110351.

16.

A role for IL-27 in limiting T regulatory cell populations.

Wojno ED, Hosken N, Stumhofer JS, O'Hara AC, Mauldin E, Fang Q, Turka LA, Levin SD, Hunter CA.

J Immunol. 2011 Jul 1;187(1):266-73. doi: 10.4049/jimmunol.1004182. Epub 2011 May 27.

17.

Complex interactions in EML cell stimulation by stem cell factor and IL-3.

Ye ZJ, Gulcicek E, Stone K, Lam T, Schulz V, Weissman SM.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4882-7. doi: 10.1073/pnas.1018002108. Epub 2011 Mar 7.

18.

Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).

Rosen DB, Minden MD, Kornblau SM, Cohen A, Gayko U, Putta S, Woronicz J, Evensen E, Fantl WJ, Cesano A.

PLoS One. 2010 Oct 27;5(10):e13543. doi: 10.1371/journal.pone.0013543.

19.

Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia.

Rosen DB, Putta S, Covey T, Huang YW, Nolan GP, Cesano A, Minden MD, Fantl WJ.

PLoS One. 2010 Aug 25;5(8):e12405. doi: 10.1371/journal.pone.0012405.

20.

Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.

Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen A, Covey T, Spellmeyer DC, Fantl WJ, Gayko U, Cesano A.

Clin Cancer Res. 2010 Jul 15;16(14):3721-33. doi: 10.1158/1078-0432.CCR-10-0093. Epub 2010 Jun 4.

Supplemental Content

Support Center